Potential Mechanisms of SGLT2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.

Pabel, Steffen; Hamdani, Nazha; Singh, Jagdeep; Sossalla, Samuel

Pabel, Steffen; Hamdani, Nazha; Singh, Jagdeep; Sossalla, Samuel.

Afiliação

Pabel S; Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Hamdani N; Department of Molecular and Experimental Cardiology, Institut für Forschung und Lehre (IFL), Ruhr University Bochum, Bochum, Germany.
Singh J; Department of Cardiology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Sossalla S; The Heart Centre, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.

Front Physiol ; 12: 752370, 2021.

Article em En | MEDLINE | ID: mdl-34803735

Palavras-chave

HFpEFheart failure with preserved ejection fraction; SGLT2 inhibitors; diastolic function; heart failure; inflammation; oxidative stress

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Front Physiol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha